LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Akciju saraksts・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Atvērts

8.47 -1.97

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.41

Max

8.6

Galvenie mērījumi
By Trading Economics
Ienākumi	4.2M -23M
Peļņas marža	-2,027.003
Darbinieki	83
EBITDA	6.6M -23M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+57.77% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	41M 628M
Iepriekšējā atvēršanas cena	10.44
Iepriekšējā slēgšanas cena	8.47

Ventyx Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025. g. 10. dec. 21:46 UTC

Peļņas

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025. g. 10. dec. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 23:43 UTC

Tirgus saruna

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025. g. 10. dec. 23:36 UTC

Tirgus saruna

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025. g. 10. dec. 23:20 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025. g. 10. dec. 23:15 UTC

Peļņas

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025. g. 10. dec. 22:59 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025. g. 10. dec. 22:45 UTC

Tirgus saruna

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025. g. 10. dec. 22:40 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:00 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025. g. 10. dec. 21:53 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 10. dec. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 21:33 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025. g. 10. dec. 21:32 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025. g. 10. dec. 21:25 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025. g. 10. dec. 21:16 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025. g. 10. dec. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025. g. 10. dec. 21:15 UTC

Peļņas

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Salīdzinājums

Cenas izmaiņa

Ventyx Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

57.77% augšup

Prognoze 12 mēnešiem

Vidējais 13.71 USD 57.77%

Augstākais 21 USD

Zemākais 2 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.